Dr. Karthik Vikram Giridhar, MD

Dr. Giridhar practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Giridhar's NPI, 1962778183, was assigned on April 2, 2012. Dr. Giridhar graduated from University of Pittsburgh School of Medicine in 2012. Dr. Giridhar holds Minnesota license 59131.

Dr. Giridhar's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Giridhar's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Giridhar is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Giridhar to 1 more clinical lab and 1 hospice, each named with a free account. Dr. Giridhar's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Giridhar practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Giridhar's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Giridhar is licensed in Minnesota.

Dmand AI lists breast cancer and lung cancer among the conditions Dr. Giridhar treats.

CMS data shows 48,892 Medicare services from Dr. Giridhar across 41 procedure codes in 2024, for 470 Medicare patients. Medicare paid $769,376 for them. Every service was in an office.

CMS counts 470 Medicare patients who saw Dr. Giridhar in 2024. The largest group is 65 to 74, with 255 patients. 64% of them have high blood pressure, and 60% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Giridhar's median patient age at 64, with 75% women.

In 2024, Dr. Giridhar wrote 274 Medicare Part D claims for 79 patients. 80% of them were for generic drugs. CMS names the drug for 200 of them, across 7 drugs with 11 or more claims each, at $444,924 in total drug cost. In 2023, CMS named 168 claims across 6 drugs.

Dr. Giridhar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Giridhar as offering telehealth.

Dmand AI links 45 papers to Dr. Giridhar, published from 2011 to 2025. 2024 was the busiest year, with 10. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Antineoplastic Agents. Dr. Giridhar has published most often in Breast Cancer Res Treat. Dr. Giridhar's most frequent co-authors are Kathryn Jean Ruddy, MD, MPH, Judy C. Boughey, MD and Tufia Christine Haddad, MD.

Dmand AI links Dr. Giridhar to 4 clinical trials, 2 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Endometrial Neoplasms. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Giridhar that name 2 trials.

CMS Open Payments shows 52 general payments to Dr. Giridhar from 8 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 68% of the total. Novartis Pharmaceuticals Corporation paid the most, $23,827. It also lists 7 research payments totaling $69,898 from 2020 to 2024, naming 2 clinical trials.

Dr. Giridhar graduated from University of Pittsburgh School of Medicine in 2012.

Dr. Giridhar is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.